SMS Pharmaceuticals Limited has announced the incorporation of its wholly owned subsidiary, SMS coLab Private Limited. The Ministry of Corporate Affairs approved the incorporation on December 23rd, 2025, with confirmation received on December 24th, 2025. The new entity, with CIN U21000TS2025PTC208449, has an authorized capital of ₹15,00,000 and a paid-up share capital of ₹1,00,000, consisting of 10,000 equity shares of ₹10 each. SMS coLab Private Limited is intended to operate as a Greenfield project for manufacturing pharmaceutical products in new therapeutic categories. Its main objects include research, development, formulation, marketing, production, manufacturing, commercialization, and distribution of pharmaceuticals, intermediates, drugs, bulk drugs, and medicines. The subsidiary will also focus on fabricating, manufacturing, buying, selling, importing, exporting, and dealing in pharmaceutical products, active pharmaceutical ingredients, chemicals, and medical equipment. Additionally, it aims to establish strategic partnerships and joint ventures globally to expand market reach and enhance product offerings. The company will hold 100% of the equity stake in SMS coLab Private Limited. Mr. Vamsi Krishna Potluri, Executive Director of SMS Pharmaceuticals Limited, is also a Director in the newly incorporated subsidiary. The acquisition, involving a 100% initial subscription to the share capital in cash by SMS Pharmaceuticals Limited for a consideration of ₹1,00,000, is considered an arm's length transaction. The subsidiary has been incorporated in India and is yet to commence business operations.